NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging ...

The ophthalmic nerve is the first branch of the trigeminal nerve, which is also known as the fifth cranial nerve. The ophthalmic nerve supplies sensory innervation to the structures of the eye, ...

Glaukos Corporation , an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the ...

EDTA has gained use in ophthalmic solutions owing to its ability to bind metals. Therapeutically, EDTA has been used to remove calcified plaques that occur in the superficial cornea in band ...

In 2024, we saw another proactive year for some of the biggest names in medtech as they looked to bolster their ranks through ...

Age-related macular degeneration (AMD) is the leading cause of vision loss in individuals over 65, characterized by abnormal ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today ...

Lufepirsen is under clinical development by Amber Ophthalmics and currently in Phase II for Persistent Corneal Epithelial Defects.

A new eye drop therapy offers a non-invasive alternative for treating dry age-related macular degeneration. Massively ...

An assortment of different preservative formulations has been used in ophthalmic medicines and many of these preservatives have been linked to unwanted ocular surface side effects. Benzalkonium ...

The research team led by Dr. Moon-Hyeong Seo from the Natural Product Drug Development Center at the Korea Institute of ...